Astellas walks away from $450M+ Cytokinetics pact after taking a few extra months to see progress

Months after losing longtime partner Amgen on its lead heart drug, Cytokinetics is waving goodbye to another ally — and with it, more than $450 million in potential milestones.

Cytokinetics revealed in an SEC filing last week that Astellas is walking away from a pact to research and develop...

Click to view original post